HRH1 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell pool with targeted disruption of the HRH1 gene in the LoVo colorectal adenocarcinoma line. This loss-of-function model enables investigation of histamine receptor H1 signaling in a colorectal cancer context. The polyclonal population contains a spectrum of knockout alleles, reflecting editing heterogeneity and ensuring comprehensive loss-of-function coverage. The heterogeneous cell mixture facilitates robust population-level analysis without clonal artifacts.
The parental LoVo cell line was established from a metastatic lymph node of a 56-year-old Caucasian male with colon adenocarcinoma, representing a mucinous colorectal cancer model. It carries well-characterized mutations in APC and KRAS, along with other cancer-related genes, and displays aggressive metastatic features such as anchorage-independent growth and invasion. LoVo cells serve as a widely used platform for studying colorectal cancer progression, metastasis, and therapeutic resistance.
HRH1 encodes the histamine H1 receptor, a G??q/11-coupled GPCR that, upon histamine binding, undergoes conformational change and activates phospholipase C beta (PLC??). PLC?? hydrolyzes phosphatidylinositol 4,5-bisphosphate to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates conventional and novel protein kinase C (PKC) isoforms. PKC phosphorylates downstream kinases, leading to ERK1/2 activation and NF-??B nuclear translocation. These transcriptional programs upregulate expression of c-Myc, MMP9, and VEGF, promoting proliferation, invasion, and angiogenesis. Receptor signaling is regulated by G protein-coupled receptor kinase 2 (GRK2)-mediated phosphorylation, which recruits ??-arrestin2, leading to receptor desensitization and internalization.
In the LoVo colorectal adenocarcinoma context, histamine derived from tumor-infiltrating mast cells activates HRH1 to drive intracellular signaling that enhances malignant properties. HRH1 engagement stimulates G??q/11-PLC??-PKC cascades, culminating in ERK and NF-??B activation and consequent transcriptional induction of c-Myc, MMP9, and VEGF. These factors cooperatively promote cell cycle progression, extracellular matrix degradation, and neovascularization. Disruption of HRH1 in this polyclonal knockout pool abolishes histamine-induced calcium mobilization and downstream kinase activation, resulting in attenuated proliferation, migration, and angiogenic factor secretion. This loss-of-function model thus provides a defined system to dissect HRH1-mediated oncogenic contributions and to assess its role in tumor-stroma communication during colorectal cancer metastasis.
These polyclonal HRH1-knockout LoVo cells are suitable for a range of functional assays. Histamine-stimulated calcium flux can be measured using fluorescent indicators to assess proximal signaling, while downstream pathway activity is evaluated by phospho-ERK western blotting. Cell proliferation is quantifiable via MTT or BrdU incorporation assays, and migratory/invasive capacity can be examined in transwell chambers. Transcriptional outputs of NF-??B activation are amenable to luciferase reporter assays, and RT-qPCR enables quantification of target genes such as c-Myc and MMP9. This model supports research into GPCR-driven oncogenic mechanisms, identification of HRH1-dependent biomarkers, screening of antihistamine compounds, and studies of tumor microenvironment interactions. For further details, contact Ascent Research.
